3-(溴甲基)苯氧基乙酸 | 136645-25-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(溴甲基)苯氧基乙酸
• 中文别名: 3-溴甲基苯氧基乙酸
• 英文名称: 3-(bromomethyl)phenoxyacetic acid
• 英文别名: 3-bromomethylphenoxyacetic acid；2-[3-(bromomethyl)phenoxy]acetic acid
• CAS: 136645-25-5
• 化学式: C₉H₉BrO₃
• 分子量: 245.073
• InChiKey: MSTODKGDFXWAIO-UHFFFAOYSA-N

物化性质

• 熔点：
  124°C
• 沸点：
  362.5±22.0 °C(Predicted)
• 密度：
  1.590±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规格正确使用和储存，则不会分解，也未有已知的危险反应。请避免与氧化物或碱接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2918990090
• 包装等级：
  II
• 危险品运输编号：
  UN 3261
• 储存条件：
  保持贮藏器密封，并将其存放在阴凉、干燥的地方。确保工作间有良好的通风或排气装置。

反应信息

• 作为反应物：
  描述：

  3-(溴甲基)苯氧基乙酸 、 喜树碱 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以72.7%的产率得到camptothecin-20-O-3-bromomethylphenoxyacetate
  参考文献：
  名称：

  Camptothecin derivatives

  摘要：

  紫杉醇类似物的(20S)酯类化合物已提供。这些化合物是紫杉醇和氧烷羧酸的(20S)酯类，紫杉醇在7、9、10、11和12位的环上可选择性地被取代。这些化合物可用于治疗癌症。

  公开号：

  US06350756B1

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• Quinolines useful in treating cardiovascular disease
  申请人：Collini D. Michael

  公开号：US20050131014A1

  公开（公告）日：2005-06-16

  This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

  本发明提供了式I化合物的用途，它们在治疗或抑制LXR介导的疾病中是有用的。
• N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
  申请人：——

  公开号：US20030158256A1

  公开（公告）日：2003-08-21

  Compounds of the formula (I), wherein R 1 is aryl or biaryl; R 2 is aryl-lower alkyl, biaryl-lower alkyl, benzo-fused cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C 2 -C 7 -alkyl in which C 2 -C 7 -alkyl is interrupted by Y; Y is O, S, SO, SO 2 , CO or NR 6 ; R 3 is hydrogen or lower alkyl; or R 2 and R 3 combined are C 2 -C 7 -alkylene or C 2 -C 7 -alkylene interrupted by Y; R 4 is hydrogen or lower alkyl; R 5 is hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, biaryl-lower alkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C 2 -C 7 -alkyl in which C 2 -C 7 -alkyl is interrupted by Y; R 6 is hydrogen, lower alkyl or aryl-lower alkyl; and pharmaceutically acceptable salts thereof, which are useful as cysteine cathepsin inhibitors.

  式（I）的化合物，其中R1是芳基或联苯基；R2是芳基-较低烷基，联苯基-较低烷基，苯并环烷基，环烷基-较低烷基，双环烷基-较低烷基，芳氧基-较低烷基，或芳基-C2-C7-烷基，其中C2-C7-烷基被Y中断；Y是O，S，SO，SO2，CO或NR6；R3是氢或较低烷基；或R2和R3结合形成C2-C7-烷基或C2-C7-烷基被Y中断；R4是氢或较低烷基；R5是氢，可选择取代的较低烷基，芳基-较低烷基，联苯基-较低烷基，环烷基-较低烷基，双环烷基-较低烷基，芳氧基-较低烷基，或芳基-C2-C7-烷基，其中C2-C7-烷基被Y中断；R6是氢，较低烷基或芳基-较低烷基；及其药学上可接受的盐，可用作半胱氨酸蛋白酶抑制剂。
• Novel quaternary ammonium compounds
  申请人：Sasahara Takehiko

  公开号：US20050009805A1

  公开（公告）日：2005-01-13

  [Object] To provide a medicine useful for treatment and prevention of hyperlipidemia, further for the treatment and prevention of cholestasis-accompanying hepatopathy, particularly primary biliary cirrhosis and primary sclerosing cholangitis, and for the treatment and prevention of obesity and fatty liver. [Means] A benzothiazepine compound represented by the following formula (1), having a thioamide bond and a quaternary ammonium substituent.

  提供一种用于治疗和预防高脂血症，尤其是原发性胆汁性肝病，特别是原发性胆汁性肝硬化和原发性硬化性胆管炎，以及治疗和预防肥胖和脂肪肝的药物。代表如下式（1）的苯并噻二唑化合物，具有硫酰胺键和季铵基取代基。
• [EN] N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS<br/>[FR] UTILISATION DE PEPTIDYL NITRILES A SUBSTITUTION- N COMME INHIBITEURS DES CATHEPSINES DE CYSTEINE
  申请人：NOVARTIS AG

  公开号：WO2001087828A1

  公开（公告）日：2001-11-22

  Compounds of the formula (I), wherein R1 is aryl or biaryl; R2 is aryl-lower alkyl, biaryl-lower alkyl, benzo-fused cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C2-C7-alkyl in which C2-C7-alkyl is interrupted by Y; Y is O, S, SO, SO2, CO or NR6; R3 is hydrogen or lower alkyl; or R2 and R3 combined are C2-C7-alkylene or C2-C7-alkylene interrupted by Y; R4 is hydrogen or lower alkyl; R5 is hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, biaryl-lower alkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C2-C7-alkyl in which C2-C7-alkyl is interrupted by Y; R6 is hydrogen, lower alkyl or aryl-lower alkyl; and pharmaceutically acceptable salts thereof, which are useful as cysteine cathepsin inhibitors.

  该式化合物（I）的化合物，其中R1是芳基或双芳基；R2是芳基-较低烷基，双芳基-较低烷基，苯并环烷基，环烷基-较低烷基，双环烷基-较低烷基，芳氧基-较低烷基，或芳基-C2-C7-烷基，其中C2-C7-烷基被Y中断；Y是O，S，SO，SO2，CO或NR6；R3是氢或较低烷基；或R2和R3结合是C2-C7-亚烷基或C2-C7-亚烷基，其中被Y中断；R4是氢或较低烷基；R5是氢，可选择性取代的较低烷基，芳基-较低烷基，双芳基-较低烷基，环烷基-较低烷基，双环烷基-较低烷基，芳氧基-较低烷基，或芳基-C2-C7-烷基，其中C2-C7-烷基被Y中断；R6是氢，较低烷基或芳基-较低烷基；以及其药学上可接受的盐，它们可用作半胱氨酸蛋白酶抑制剂。